Exact Mass: 467.043676
Exact Mass Matches: 467.043676
Found 42 metabolites which its exact mass value is equals to given mass value 467.043676,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
AG 2034
(2S)-2-[[5-[2-[(6S)-2-Amino-4-oxo-1,6,7,8-tetrahydropyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
FK-614
C21H23Cl2N3O3S (467.08371080000006)
3-[[4-(2,4,6-trinitroanilino)benzoyl]amino]benzoic acid
C20H13N5O9 (467.07132480000007)
2 6-DICHLORO-4-(2 4 6-TRIPHENYL-1-PYRI-&
C29H19Cl2NO (467.08436240000003)
disodium,3-[4-[(5-nitropyridin-2-yl)diazenyl]-3-oxido-N-propylanilino]propane-1-sulfonate
(5AS, 10BR)-(-)-5A,10B-DIHYDRO-2-(PENTAFLUOROPHENYL)-4H,6H-INDENO[2,1-B][1,2,4]TRIZOLO[4,3-D][1,4]OXAZINIUM TETRAFLUOROBORATE
dimethyl 2-[[1-(4-chlorobenzoyl)-2-(trifluoromethyl)indol-3-yl]methyl]propanedioate
C22H17ClF3NO5 (467.07472980000006)
2-Pentafluorophenyl-6,10b-dihydro-4H,5aH-5-oxo-3,10c-diaza-2-azoniacyclopenta[c]fluorine tetrafluoroborate
1-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-1H-benzo[d]imidazole-6-carboxamide
C21H23Cl2N3O3S (467.08371080000006)
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes[1][2].
N-[4-(4-fluorophenyl)-2-thiazolyl]-2-[(4-methylphenyl)sulfonylamino]benzamide
C23H18FN3O3S2 (467.07735699999995)
4-(Dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid
2-[[5-[2-(2-Amino-4-oxo-3,6,7,8-tetrahydropyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
8-Demethyl-8-formylriboflavin 5-phosphate
C17H16N4O10P-3 (467.06040260000003)
2-(3-Hydroxymercurio-2-methoxypropylcarbamoyl)phenoxyacetic acid
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-3,3-dichloro-1H-indol-2-one
C20H19Cl2N3O4S (467.0473274000001)
2-[[5-[[2-(3-Chloroanilino)-4-thiazolyl]methyl]-4-(3-methoxypropyl)-1,2,4-triazol-3-yl]thio]acetic acid methyl ester
C19H22ClN5O3S2 (467.08525320000007)
3-Bromo-5-[[4-[hydroxy(diphenyl)methyl]-1-piperidinyl]-oxomethyl]-2-pyranone
C24H22BrNO4 (467.07321120000006)
3-[4-(4-Morpholinylsulfonyl)phenyl]propanoic acid [2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl] ester
C20H22ClN3O6S (467.0917782000001)
2-[[5-(3-Bromophenyl)-4-phenyl-1,2,4-triazol-3-yl]thio]-1-(4-fluorophenyl)ethanone
C22H15BrFN3OS (467.01031720000003)
5-[(3-Carboxylato-5-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)(2-sulfonatophenyl)methyl]-2-hydroxy-3-methylbenzoate
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 3-hydroxybenzoate
L-Glutamic acid, N-((5-(2-((6S)-2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido(5,4-b)(1,4)thiazin-6-yl)ethyl)-2-thienyl)carbonyl)-
Lp-PLA2-IN-3
C20H13ClF3N3O3S (467.0318214000001)
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2)[1].